Posted by Michael Wonder on 01 Jun 2023
Antengene announces Xpovio plus bortezomib and dexamethasone included for reimbursement by the PBS in Australia for the treatment of relapsed and/or refractory multiple myeloma
31 May 2023 - This inclusion by the PBS for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy is the second inclusion of Xpovio by the PBS.
Antengene today announced that Xpovio (selinexor) in combination with bortezomib and dexamethasone is now listed on the PBS for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least one prior therapy.
